Recommendations for the treatment of factor VIII inhibitors: From the UK Haemophilia Centre Directors' Organisation Inhibitor Working Party

Blood Coagulation and Fibrinolysis

Volumn 7, Issue 2, 1996, Pages 134-138

  Hay, C R M ^a   Colvin, B T ^b   Ludlam, C A ^c   Hill, F G H ^d   Preston, F E ^e  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^b ROYAL LONDON HOSPITAL   (United Kingdom)

^c ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^d BIRMINGHAM CHILDREN S HOSPITAL   (United Kingdom)

^e ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

Factor VIII inhibitors; Haemophilia; Therapeutic recommendations

Indexed keywords

AUTOANTIBODY; BLOOD CLOTTING FACTOR 8 INHIBITOR;

CHILD; HEMOPHILIA; HUMAN; INFANT; PRIORITY JOURNAL; SCREENING; SHORT SURVEY;

EID: 0029998402     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-199603000-00005     Document Type: Short Survey

References (33)

1. Rizza CR, Spooner RGD. Treatment of haemophilia and related disorders in Britain and Northern Ireland during 1976-80: report on behalf of the Directors of Haemophilia Centres in the United Kingdom. Br Med J 1983; 286: 929-934.
2. Rasi V, Ikkala E. Haemophiliacs with factor VIII inhibitors in Finland: prevalence, incidence and outcome. Br J Haematol 1990; 76: 369-371.
3. Biggs R, Austen DEG, Denson KWE, Rizza CR, Borret R. The mode of action of antibodies which destroy factor VIII. II. Antibodies which give complex concentration graphs. Br J Haematol 1972; 23: 137-155.
4. McMillan CW, Shapiro SS, Whitehurst D, Hoyer LW, Rao V, Lazerson J, and the Hemophilia Study Group. The natural history of factor VIII inhibitors in patients with hemophilia A: a national cooperative study. II. Observations on the initial development of factor VIII:C inhibitors. Blood 1988; 71: 344-351.
5. Ehrenforth S, Kreuz W, Scharrer I, et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 594-598.
6. Lusher JM, Arkin S, Abildgaard CF, Schwartz RS. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. N Engl J Med 1993: 328: 453-459.
7. Addiego J, Kasper C, Abildgaard C, et al. Frequency of inhibitor development in haemophiliacs treated with lowpurity factor VIII. Lancet 1993; 342: 462-464.
8. Margolius A, Jackson DP, Ratnoff OD. Circulating anticoagulants: a study of 40 cases and review of the literature. Medicine 1961; 40: 145-202.
9. Lottenberg R, Kentro TB, Kitchens CS. A natural history study of 16 patients with factor VIII inhibitors receiving little or no therapy. Arch of Int Med 1987; 147: 1077-1081.
10. Green D, Lechner K. A survey of 214 non-hemophilic patients with inhibitors to factor VIII. Thromb Haemost 1981; 45: 200-203.
11. Kasper CK, Aledort LM, Counts RB, et al. A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975; 34: 869-872.
12. NHS Management Executive Health Service Guidelines, HSG (93)30. Provision of haemophilia treatment and care. BAPS Health Publications Unit, Crown Copyright, 1993.
13. Mauser-Bunschoten EP, Niewenhuis HK, Roosendaal G, van den Berg HM. Low-dose immune tolerance induction in haemophilia A patients with inhibitors. Blood 1995; 86: 983-988.
14. Brackmann HH. Induced immunotolerance in factor VIII inhibitor patients. Clin Biol Res 1986; 50: 181-195.
15. Nilsson IM, Berntorp E, Zettervall O. Induction of immune tolerance in patients with haemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide and factor VIII. N EnglJ Med 1988; 318: 947-950.
16. Mariani G, Ghirardini A, Belloco R. Immune tolerance in hemophilia. Principal results from the international registry. Thromb Haemost 1994; 72.
17. Kreutz W, Ehrenforth S, Funk M, et al. Immune tolerance therapy in paediatric haemophiliacs with factor VIII inhibitors: 14 years follow-up. Haemophilia 1995; 1: 24-32.
18. Mariani G, Brackmann HH, eds. Immune tolerance and the treatment of hemophiliacs with an inhibitor: proceedings of the workshop on immune tolerance. Vox Sang 1996; 70: (suppl): 60-65.
19. Lusher JM, Shapiro SS, Palascak JE, Rao AV, Levine PH, Blatt PM, and the Haemophilia Study Group. Efficacy of prothrombin complex concentrates in hemophiliacs with antibodies to factor VIII: a multicenter therapeutic trial. N Engl J Med 1980; 303: 421-425.
20. Lusher JM. Use of prothrombin complex concentrates in management of bleeding in hemophiliacs with inhibitors-benefits and limitations. Semin Haematol 1994; 31: 49-52.
21. Hedner U, Glazer S, Falch J. Recombinant activated factor VII in the treatment of bleeding episodes in patients with inherited and acquired bleeding disorders. Transfusion Med Rev 1993: 7: 78-83.
22. Hay CRM, Lozier JN, Lee CA, et al. Safety profile of porcine factor VIII and its use as hospital and home-therapy for patients with haemophilia A and inhibitors: the results of an international survey. Thromb Haemost 1996; 75 (in press).
23. Morrison AE, Ludlam CA, Kessler C. Use of porcine factor VIII in the treatment of patients with acquired hemophilia. Blood 1993; 81: 1513-1520.
24. Bona RD, Riberio M, Klatsky AU, Panek S, Magnifico M, Rickles FR. Continuous infusion of porcine factor VIII for the treatment of patients with factor VIII inhibitors. Semin Haematol 1993; 30: 32-35.
25. Macik BG, Lindley CM, Lusher J, et al. Safety and initial efficacy of three dose levels of recombinant activated factor VII (rFVIIa): results of a phase 1 study. Blood Coag Fibrinol 1993; 4: 521-527.
26. Doughty HA, Northeast A, Sklaire L, et al. The use of recombinant factor VIIa in a patient with acquired haemophilia A undergoing surgery. Blood Coag Fibrinol 1995; 6: 125-128.
27. Sultan Y, Kazatchkine MD, Caisonneuve P, Nydegger UE. Anti-idiorype suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous immunoglobulin. Lancet 1984; ii: 765-768.
28. Sultan Y, Rossi F, Kazatchine MD. Recovery from antiVIIIC (antihemophilic factor) autoimmune disease is dependant on generation of antiidiorypes against antiVIIIC autoantibodies. Proc Natl Acad Sci USA 1987; 84: 828-831.
29. Green D. Factor VIII antibodies: immunosuppressive therapy. Ann NY Acad Sci 1975; 240: 389-399.
30. Spero JA, Lewis JH, Hasiba U. Corticosteroid therapy for acquired F VIIIC inhibitors. Br J Haematol 1981; 48: 635-642.
31. Lian ECY, Larcada AF, Chiu AYZ. Combination immunosuppressive therapy after factor VIII infusion for acquired factor VIII inhibitor. Ann Int Med 1989; 110: 774-778.
32. Lipton RA. The economics of factor VIII inhibitor treatment. Semin Haematol 1994; 31: 41-43.
33. Rivard GE, Vick S. Economics of inhibitor treatment in Canada. Semin Haematol 1994; 31: 41-43.